Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Breast Cancer

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 43 articles:
HTML format



Single Articles


    March 2023
  1. KWAPISZ D, Verret B, Garcia C, Andre F, et al
    Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation.
    Ann Oncol. 2023;34:315-318.
    PubMed    


    January 2023
  2. LUEN SJ, Viale G, Nik-Zainal S, Savas P, et al
    Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
    Ann Oncol. 2023 Jan 25:S0923-7534(23)00047-9. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available


  3. REICHERT ZR, Morgan TM, Li G, Castellanos E, et al
    Prognostic value of plasma circulating tumor DNA fraction across four common cancer types: a real-world outcomes study.
    Ann Oncol. 2023;34:111-120.
    PubMed     Abstract available


    December 2022
  4. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 3
    Ann Oncol. 2022 Dec 21:S0923-7534(22)04773-1. doi: 10.1016/j.annonc.2022.
    PubMed    


  5. VAN BAELEN K, Geukens T, Maetens M, Tjan-Heijnen V, et al
    Corrigendum to "Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer": [Annals of Oncology 33 (2022) 769-785].
    Ann Oncol. 2022 Dec 16:S0923-7534(22)04746-9. doi: 10.1016/j.annonc.2022.
    PubMed    


  6. LOVEDAY C, Garrett A, Law P, Hanks S, et al
    Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
    Ann Oncol. 2022;33:1318-1327.
    PubMed     Abstract available


    November 2022
  7. TURNER NC, Swift C, Jenkins B, Kilburn L, et al
    Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate and high-risk early stage triple negative breast cancer.
    Ann Oncol. 2022 Nov 21:S0923-7534(22)04735-4. doi: 10.1016/j.annonc.2022.
    PubMed     Abstract available


  8. BIANCHINI G, Licata L, Viale G, Gianni L, et al
    Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions.
    Ann Oncol. 2022;33:1091-1093.
    PubMed    


  9. AUGUSTIN JE, Soussan P, Bass AJ
    Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma.
    Ann Oncol. 2022;33:1134-1148.
    PubMed     Abstract available


    October 2022
  10. SESSA C, Balmana J, Bober SL, Cardoso MJ, et al
    Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04193.
    PubMed    


  11. GEYER CE JR, Garber JE, Gelber RD, Yothers G, et al
    Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high risk, early breast cancer.
    Ann Oncol. 2022 Oct 10. pii: S0923-7534(22)04165.
    PubMed     Abstract available


    August 2022
  12. LOIBL S, Schneeweiss A, Huober J, Braun M, et al
    Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
    Ann Oncol. 2022 Aug 9. pii: S0923-7534(22)03791.
    PubMed     Abstract available


  13. PALUCH-SHIMON S, Cardoso F, Partridge AH, Abulkhair O, et al
    ESO-ESMO 5(th) International Consensus Guidelines for Breast Cancer in Young Women (BCY5).
    Ann Oncol. 2022 Aug 4. pii: S0923-7534(22)01858.
    PubMed     Abstract available


    June 2022
  14. DING K, Chen F, Priedigkeit N, Brown DD, et al
    Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine.
    Ann Oncol. 2022 Jun 25. pii: S0923-7534(22)01734.
    PubMed    


    May 2022
  15. VAN BAELEN K, Geukens T, Maetens M, Tjan-Heijnen V, et al
    Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer.
    Ann Oncol. 2022 May 20. pii: S0923-7534(22)01167.
    PubMed     Abstract available


  16. LOIBL S, Untch M, Burchardi N, Huober J, et al
    Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of Onco
    Ann Oncol. 2022 May 17. pii: S0923-7534(22)00676.
    PubMed    


  17. MARCZYK M, Mrukwa A, Yau C, Wolf D, et al
    Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
    Ann Oncol. 2022 May 2. pii: S0923-7534(22)00762.
    PubMed     Abstract available


    April 2022
  18. TARANTINO P, Jin Q, Mittendorf EA, King TA, et al
    Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib.
    Ann Oncol. 2022 Apr 28. pii: S0923-7534(22)00754.
    PubMed    


  19. PICCART MJ, Kalinsky K, Gray R, Barlow WE, et al
    Erratum to "Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust": [Annals of Oncology 32 (2021) 1077-1082].
    Ann Oncol. 2022 Apr 26. pii: S0923-7534(22)00673.
    PubMed    


  20. GEYER CE, Sikov WM, Loibl S
    Reply to the Letter to the Editor "Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer" by A. Okines and N. Turner.
    Ann Oncol. 2022 Apr 4. pii: S0923-7534(22)00671.
    PubMed    


    March 2022
  21. RUGO HS, O'Shaughnessy J, Boyle F, Toi M, et al
    Adjuvant Abemaciclib Combined with Endocrine Therapy for High Risk Early Breast Cancer: Safety and Patient-Reported Outcomes From the monarchE Study.
    Ann Oncol. 2022 Mar 22. pii: S0923-7534(22)00383.
    PubMed     Abstract available


  22. TOMASIK B, Bienkowski M, Jassem J
    Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the die has not been cast.
    Ann Oncol. 2022 Mar 16. pii: S0923-7534(22)00384.
    PubMed    


  23. FLEMING GF, Pagani O, Regan MM, Walley BA, et al
    Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00380.
    PubMed    


  24. OKINES A, Turner N
    Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer.
    Ann Oncol. 2022 Mar 14. pii: S0923-7534(22)00364.
    PubMed    


  25. ZANELLI S, Fiorio E, Zampiva I, Zacchi F, et al
    Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona.
    Ann Oncol. 2022 Mar 8. pii: S0923-7534(22)00363.
    PubMed    


    February 2022
  26. GIANNI L, Huang CS, Egle D, Bermejo B, et al
    Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.
    Ann Oncol. 2022 Feb 16. pii: S0923-7534(22)00113.
    PubMed     Abstract available


    January 2022
  27. GEYER CE JR, Sikov WM, Huober J, Rugo HS, et al
    Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.
    Ann Oncol. 2022 Jan 27. pii: S0923-7534(22)00018.
    PubMed     Abstract available


  28. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    PubMed     Abstract available


  29. GAO JJ, Krol D, Narayan P, Cardoso F, et al
    Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(22)00002.
    PubMed    


  30. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertu
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(21)04883.
    PubMed    


    December 2021
  31. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.
    Ann Oncol. 2021 Dec 22. pii: S0923-7534(21)04879.
    PubMed     Abstract available


  32. TARANTINO P, Burstein HJ, Lin NU, Krop IE, et al
    Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
    Ann Oncol. 2021 Dec 20. pii: S0923-7534(21)04877.
    PubMed    


  33. SPRING L, Matikas A, Bardia A, Foukakis T, et al
    Adjuvant abemaciclib for high-risk breast cancer: the story continues.
    Ann Oncol. 2021;32:1457-1459.
    PubMed    


    November 2021
  34. CARDOZO JMNL, Byng D, Drukker CA, Schmidt MK, et al
    Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04829.
    PubMed     Abstract available


  35. POGGIO F, Tagliamento M, Ceppi M, Bruzzone M, et al
    Adding a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer: the end of the debate.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04831.
    PubMed    


  36. HAN HS, Arun BK, Kaufman B, Wildiers H, et al
    Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04833.
    PubMed     Abstract available


  37. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
    Ann Oncol. 2021 Nov 2. pii: S0923-7534(21)04520.
    PubMed    


    October 2021
  38. HARBECK N, Rastogi P, Shahir A, Johnston S, et al
    Letter to the Editor for "Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study".
    Ann Oncol. 2021 Oct 28. pii: S0923-7534(21)04551.
    PubMed    


  39. FUENTES-ANTRAS J, Cescon DW
    PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.
    Ann Oncol. 2021 Oct 19. pii: S0923-7534(21)04523.
    PubMed    


  40. GENNARI A, Andre F, Barrios CH, Cortes J, et al
    ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
    Ann Oncol. 2021 Oct 13. pii: S0923-7534(21)04498.
    PubMed    


  41. HE W, Eriksson M, Eliasson E, Grassmann F, et al
    CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
    Ann Oncol. 2021;32:1286-1293.
    PubMed     Abstract available


    September 2021
  42. HARBECK N, Rastogi P, Martin M, Tolaney SM, et al
    Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04494.
    PubMed     Abstract available


  43. WANG Y, Acs B, Robertson S, Liu B, et al
    Improved breast cancer histological grading using deep learning.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04486.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: